RxDoctor Payments Data

Martha Drohobyczer, CNM

Psychiatric/Mental Health, Adult · Las Vegas, NVNPI 1184707077

Payments from drug & device makers

$5,006in general payments, 2019–2025

Across 130 payments — averaging $38.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$723
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$606
  • Otsuka America Pharmaceutical, Inc.$544
  • E.r. Squibb & Sons, L.L.C.$360
  • Neurocrine Biosciences, Inc.$300
  • plus $959 from 13 others

What the payments were for

  • Food & beverage$4,95999%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychiatric/mental health, adult providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$19,984
Medicare patients
69
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole40$3,072
Paliperidone ErPaliperidone12$2,245
Divalproex Sodium54$1,045
ProgesteroneProgesterone, Micronized13$782
Trazodone Hcl34$568
Bupropion Hcl SrBupropion Hcl20$567
Buspirone Hcl23$554
Quetiapine Fumarate33$519
Medroxyprogesterone Acetate15$486
Venlafaxine Hcl ErVenlafaxine Hcl42$475
Oxcarbazepine14$459
Hydroxyzine Pamoate25$445
Estradiol19$395
Acyclovir11$387
Sertraline Hcl26$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Acyclovir$165$38711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other psychiatric/mental health, adult in Las Vegas

Where these figures come from

Is this you, or does something look wrong? →